Prasugrel resistance: fact or fiction (Q37905028)

25 August 2017

1 reference

title

Prasugrel resistance: fact or fiction (English)

1 reference

25 August 2017

Dimitrios Alexopoulos

series ordinal

1

1 reference

25 August 2017

25 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

23

1 reference

25 August 2017

2

1 reference

25 August 2017

83-90

1 reference

Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study

25 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation--a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Drug insight: Clopidogrel nonresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Can we override clopidogrel resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2011.600478

10.3109/09537104.2011.600478

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21787175